Reporting of paclitaxel-induced peripheral neuropathy symptoms to clinicians among women with breast cancer: a qualitative study.
Reporting of paclitaxel-induced peripheral neuropathy symptoms to clinicians among women with breast cancer: a qualitative study.
复制标题
DOI：
10.1007/s00520-019-05254-6
复制
发表时间：
2020-09
期刊：
影响因子：
--
通讯作者：
Hertz DL
中科院分区：
文献类型：
--
作者：
Salgado TM;Quinn CS;Krumbach EK;Wenceslao I;Gonzalez M;Reed HL;Syverson JG;Etz RS;Vangipuram K;Barker MR;Henry NL;Farris KB;Hertz DL
化疗引起的周围神经病变（CIPN）病例报告不足，在文献中零星描述，但没有研究集中在积极检查这种行为。我们的主要目的是找出故意少报CIPN的妇女，沿着这样做的原因。第二个目的是探讨因素，使或阻碍CIPN的沟通，临床医生。在一项前瞻性观察性研究中，对接受紫杉醇治疗的乳腺癌妇女进行了半结构化访谈。访谈指南是根据假设影响向临床医生披露副作用的因素制定的。访谈记录，逐字转录，并按主题进行内容分析。对34名妇女进行了访谈。分析中出现了三个主要主题：1）CIPN报告的促成因素（例如，与肿瘤团队的积极关系、充足的预约时间、办公室访问的替代沟通渠道的存在、CIPN作为副作用的预期）; 2）对CIPN报告的阻碍（例如，认为需要完成整个疗程，害怕治疗中断，缺乏对CIPN长期后果的了解）;和3）平衡存活与CIPN引起的功能损害。女性优先考虑疗效超过CIPN，直到身体功能受到有意义的影响。没有患者报告有目的的CIPN低报，但三名妇女承认曾考虑这样做。尽管缺乏CIPC保留的证据，但女性在决定是否报告CIPC症状时，会考虑紫杉醇治疗的有效性和毒性，以及对CIPC治疗和长期后果的信念以及与肿瘤团队的关系。
Cases of chemotherapy-induced peripheral neuropathy (CIPN) under-reporting have been sporadically described in the literature, but no studies have focused on actively examining this behavior. Our primary aim was to identify women who purposefully under-reported CIPN, along with reasons for doing so. A secondary aim was to explore factors enabling or hindering communication of CIPN to clinicians. Semi-structured interviews were conducted with women with breast cancer who had received paclitaxel in a prospective observational study. The interview guide was developed based on factors hypothesized to influence side effect disclosure to clinicians. Interviews were recorded, transcribed verbatim, and thematically content analyzed. Thirty-four women were interviewed. Three main themes emerged from the analysis: 1) enablers of CIPN reporting (e.g., positive relationships with the oncology team, sufficient appointment time, existence of alternative communication channels to office visits, expectation of CIPN as a side effect); 2) deterrents to CIPN reporting (e.g., perception of need to complete the full course of therapy, fear of treatment discontinuation, lack of knowledge of long-term consequences of CIPN); and 3) balancing survival versus functional impairment due to CIPN. Women prioritized efficacy over CIPN until physical functioning was meaningfully affected. No patients reported purposeful CIPN under-reporting, but three women admitted having considered doing so. Despite the lack of evidence of CIPN withholding, women considered both the effectiveness and the toxicity of paclitaxel treatment, as well as beliefs about treatment and long-term consequences of CIPN and relationship with the oncology team, when deciding whether to report CIPN symptoms.
登录
查看更多内容
影响因子：
--
作者：
Bhatnagar, Bhavana;Gilmore, Steven;Bao, Ting
通讯作者：
Bao, Ting
DOI：
10.1158/1078-0432.ccr-18-0656
发表时间：
2018-08-01
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Hertz DL;Kidwell KM;Vangipuram K;Li F;Pai MP;Burness M;Griggs JJ;Schott AF;Van Poznak C;Hayes DF;Lavoie Smith EM;Henry NL
通讯作者：
Henry NL
影响因子：
2.8
作者：
Chan, Choi Wan;Cheng, Huilin;Molassiotis, Alex
通讯作者：
Molassiotis, Alex
影响因子：
28.4
作者：
de Morree, Ellen S.;Vogelzang, Nicholas J.;de Wit, Ronald
通讯作者：
de Wit, Ronald
影响因子：
10.3
作者：
Hershman, Dawn L.;Unger, Joseph M.;Albain, Kathy S.
通讯作者：
Albain, Kathy S.